Why does Healthy Mango cover both approved drugs and unapproved research peptides?

Healthy Mango covers the full spectrum of peptides studied in scientific literature, from FDA-approved drugs (semaglutide, tirzepatide, bremelanotide) to peptides that remain in the research-supply category (BPC-157, TB-500, MOTS-c). We do this because the actual pharmacological landscape includes both, and readers benefit from understanding the difference clearly rather than being shown only one side.

Approval status does not simply reflect whether a compound has biological activity. It reflects the combination of biological effect plus commercial protectability (whether the compound is patentable enough for a pharmaceutical company to invest in phase-3 development) plus indication clarity (whether there is a defined regulatory endpoint) plus market size (whether the target patient population is large enough or supported by rare-disease incentives). Compounds that meet all four criteria — like semaglutide in obesity — reach approval. Compounds with strong preclinical biology but weak patent protection, broad rather than narrow indications, or small markets often remain in the research space regardless of scientific interest.

Distinguishing these two positions is essential for reading the catalog critically. Approved drugs come with phase-3 human evidence and regulatory oversight. Research-supply peptides come with variable evidence quality and no regulatory framework. Both can be scientifically interesting; only one has the evidence tier that would support routine clinical use.